Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny - 2These men carry towers of birds through Mexico's streets. They say their tradition is dying out.
- 3Israel and Lebanon's Hezbollah continue to trade attacks
- 4Israeli strikes on Beirut, as Hezbollah and Iran attack Israel
- 5The most effective method to Decide the Best Auto Crash Attorney for Your Lawful Necessities
- Tatiana Schlossberg, a granddaughter of JFK, is dead at 35 after cancer diagnosis
- The German series proving subtitles can be sexy — and wildly addictive
- Disney's latest short film 'Versa' tackles a difficult subject: Pregnancy loss. It's resonating with viewers.
- ‘I love this work, but it’s killing me’: The unique toll of being a spiritual leader today
- The most effective method to Integrate Compact disc Rates into Your Retirement Arranging
- Figure out How to Pick the Right Dental specialist for Your Dental Inserts
- New Jordan security fence could be done in early 2028
- Home Security Frameworks with Shrewd Elements
- Heart disease risk greater for women with a common condition they may not be aware they have
